Improving outcomes for patients with diabetic macular edema

Carmen A. Puliafito, Pravin U. Dugel, Scott W. Cousins, Kirk H. Packo, Alexander M. Eaton, Richard K Parrish, Szilárd Kiss, Elias Reichel

Research output: Contribution to journalArticle

Abstract

Diabetic macular edema (DME) is one of the most common causes of vision loss in patients who have diabetes, and all of these patients are at risk for developing DME. The onset is often painless, difficult to detect, and can occur at any stage of diabetes. Ideally, DME is preventable, but treatment must be considered when preventative methods fail. Although physicians have several different treatment options for patients with DME, some patients who receive treatment can respond poorly and may even lose vision. Until recently, laser photocoagulation was regarded as the standard of care for DME; however, pharmaceutical treatments are rapidly replacing this standard as the desire to maximize systemic treatment of DME increases. A panel of experts gathered during the 2015 annual meeting of the Association for Research in Vision and Ophthalmology for a roundtable discussion designed to focus on improving outcomes for patients with DME using pharmaceutical treatment, including the use of anti-VEGFs and corticosteroids, based on the most current research and clinical data.

Original languageEnglish (US)
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume46
Issue number10
DOIs
StatePublished - Nov 1 2015

Fingerprint

Macular Edema
Therapeutics
Vascular Endothelial Growth Factors
Light Coagulation
Standard of Care
Pharmaceutical Preparations
Adrenal Cortex Hormones
Lasers
Physicians
Research

ASJC Scopus subject areas

  • Ophthalmology
  • Surgery

Cite this

Puliafito, C. A., Dugel, P. U., Cousins, S. W., Packo, K. H., Eaton, A. M., Parrish, R. K., ... Reichel, E. (2015). Improving outcomes for patients with diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina, 46(10). https://doi.org/10.3928/23258160-20151124-01

Improving outcomes for patients with diabetic macular edema. / Puliafito, Carmen A.; Dugel, Pravin U.; Cousins, Scott W.; Packo, Kirk H.; Eaton, Alexander M.; Parrish, Richard K; Kiss, Szilárd; Reichel, Elias.

In: Ophthalmic Surgery Lasers and Imaging Retina, Vol. 46, No. 10, 01.11.2015.

Research output: Contribution to journalArticle

Puliafito, CA, Dugel, PU, Cousins, SW, Packo, KH, Eaton, AM, Parrish, RK, Kiss, S & Reichel, E 2015, 'Improving outcomes for patients with diabetic macular edema', Ophthalmic Surgery Lasers and Imaging Retina, vol. 46, no. 10. https://doi.org/10.3928/23258160-20151124-01
Puliafito, Carmen A. ; Dugel, Pravin U. ; Cousins, Scott W. ; Packo, Kirk H. ; Eaton, Alexander M. ; Parrish, Richard K ; Kiss, Szilárd ; Reichel, Elias. / Improving outcomes for patients with diabetic macular edema. In: Ophthalmic Surgery Lasers and Imaging Retina. 2015 ; Vol. 46, No. 10.
@article{0736ed36409a4d2184f4566e5f67fd24,
title = "Improving outcomes for patients with diabetic macular edema",
abstract = "Diabetic macular edema (DME) is one of the most common causes of vision loss in patients who have diabetes, and all of these patients are at risk for developing DME. The onset is often painless, difficult to detect, and can occur at any stage of diabetes. Ideally, DME is preventable, but treatment must be considered when preventative methods fail. Although physicians have several different treatment options for patients with DME, some patients who receive treatment can respond poorly and may even lose vision. Until recently, laser photocoagulation was regarded as the standard of care for DME; however, pharmaceutical treatments are rapidly replacing this standard as the desire to maximize systemic treatment of DME increases. A panel of experts gathered during the 2015 annual meeting of the Association for Research in Vision and Ophthalmology for a roundtable discussion designed to focus on improving outcomes for patients with DME using pharmaceutical treatment, including the use of anti-VEGFs and corticosteroids, based on the most current research and clinical data.",
author = "Puliafito, {Carmen A.} and Dugel, {Pravin U.} and Cousins, {Scott W.} and Packo, {Kirk H.} and Eaton, {Alexander M.} and Parrish, {Richard K} and Szil{\'a}rd Kiss and Elias Reichel",
year = "2015",
month = "11",
day = "1",
doi = "10.3928/23258160-20151124-01",
language = "English (US)",
volume = "46",
journal = "Ophthalmic Surgery Lasers and Imaging Retina",
issn = "2325-8160",
publisher = "Slack Incorporated",
number = "10",

}

TY - JOUR

T1 - Improving outcomes for patients with diabetic macular edema

AU - Puliafito, Carmen A.

AU - Dugel, Pravin U.

AU - Cousins, Scott W.

AU - Packo, Kirk H.

AU - Eaton, Alexander M.

AU - Parrish, Richard K

AU - Kiss, Szilárd

AU - Reichel, Elias

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Diabetic macular edema (DME) is one of the most common causes of vision loss in patients who have diabetes, and all of these patients are at risk for developing DME. The onset is often painless, difficult to detect, and can occur at any stage of diabetes. Ideally, DME is preventable, but treatment must be considered when preventative methods fail. Although physicians have several different treatment options for patients with DME, some patients who receive treatment can respond poorly and may even lose vision. Until recently, laser photocoagulation was regarded as the standard of care for DME; however, pharmaceutical treatments are rapidly replacing this standard as the desire to maximize systemic treatment of DME increases. A panel of experts gathered during the 2015 annual meeting of the Association for Research in Vision and Ophthalmology for a roundtable discussion designed to focus on improving outcomes for patients with DME using pharmaceutical treatment, including the use of anti-VEGFs and corticosteroids, based on the most current research and clinical data.

AB - Diabetic macular edema (DME) is one of the most common causes of vision loss in patients who have diabetes, and all of these patients are at risk for developing DME. The onset is often painless, difficult to detect, and can occur at any stage of diabetes. Ideally, DME is preventable, but treatment must be considered when preventative methods fail. Although physicians have several different treatment options for patients with DME, some patients who receive treatment can respond poorly and may even lose vision. Until recently, laser photocoagulation was regarded as the standard of care for DME; however, pharmaceutical treatments are rapidly replacing this standard as the desire to maximize systemic treatment of DME increases. A panel of experts gathered during the 2015 annual meeting of the Association for Research in Vision and Ophthalmology for a roundtable discussion designed to focus on improving outcomes for patients with DME using pharmaceutical treatment, including the use of anti-VEGFs and corticosteroids, based on the most current research and clinical data.

UR - http://www.scopus.com/inward/record.url?scp=84957795499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957795499&partnerID=8YFLogxK

U2 - 10.3928/23258160-20151124-01

DO - 10.3928/23258160-20151124-01

M3 - Article

C2 - 26653894

AN - SCOPUS:84957795499

VL - 46

JO - Ophthalmic Surgery Lasers and Imaging Retina

JF - Ophthalmic Surgery Lasers and Imaging Retina

SN - 2325-8160

IS - 10

ER -